ESMO 2023

Preoperative checkpointinihition in ER+ disease

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with…

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

Lu-PSMA leads forward

When the history of ADC is written: Redefining…

New 3rd line therapy for RCC

Amivantamab as a new SoC for EGFR Exon 20…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Perioperativ immunotherapy for all resectable stage…

My highlights from ESMO 2023

ALINA - immediate change of practice!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

Anticipated updates and exciting new data for…

New data on neoadjuvant immunotherapy

Neoadjuvant IO - is their new strategy in HR+ breast…

Metabolomics reveal differential expression of OMEGA 3…

Carry-over effects in monarchE confirmed

Ribociclib effective in all subtypes

My highlights of ESMO23 in early breast cancer

ER-low corresponds diagnostically to ER-0 breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

MonarchE - trial update

Immunoncology in eBC - triple negative and more?

Prognostic score in early HR+/HER2-BC: translational…

Negative EFS results from NeoTrip

Consolidation of data in early HR+ and triple-negative…

HR+ study with > 20 % PCR

Our guidelines are correct

5 year follow-up

Analysis of tumour microenvironment and…

Clinically relevant effect of pembro also in PCR

Use of immunotherapy in the perioperative setting of…

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

ADCs in HER2+, HER2low and TNBC - what is the future of…

What was the most exciting news at ESMO23?

New targets, new linker, new ADCs - much more to learn…

Improvement of therapy outcome by app-based patient…

How to organize a molecular tumorboards in breast…

HS20089 - a novel ADC is coming for TNBC

Duvalumab + Dato-DXd effective

My highlights of ESMO23 in metastatic breast cancer

New ADC in HR+ disease

Can surgery be spared following primary systemic…

Fulvestran better than anastrozole, but no survival…

Patient-centered molecular medicine - a new approach

Improved oncological therapy with the smartphone

DATO-DX - where is it going?

Benefit for SG even after intensive pretreatment

T-DXd - new standard of care for brain mets?

ADC + Immunotherapy - the BEGONIA study paradigm

TULIP: Trastuzumab duocarmazine without OS benefit

T-DXd in HER2+ patients with brain metastases

OP-1250 (Palezestrant) confirms the role of SIRDs after…

TROP2 expression as a potential mechanism of resistance…

Remarkable efficacies in patients with HER2+ mBC with…

T-DXd also effective for brain metastases

HER2DX in the PHERgain trial

Still on track for success in HER2-low MBC

Dato-DXd - new player in advanced luminal disease

OP seems to be dispensable for super responders

Robust data from the monarchE

Our guidelines are correct

Even more new generation ADCs in breast cancer?

Highlights in mBC

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

T-DXd - nowy standard postępowania w przerzutach do…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

La expresión de TROP2 como potencial mecanismo de…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

Lo studio BEGONIA nelle paziento con tumore triplo…

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust…

The optimal timing of RT after radical prostatectomy…

RADICALS RT: Trial and controversies

STAMPEDE. Bone prediction not for everyone - better…

CXCR2 inhibitor in PCa

IO therapy in metastatic prostate cancer.

Immunotherapy in metastatic PCa

When immunotherapy is probably not the best choice: The…

PSMAfore unleashes urooncologic opportunity

ENZA P:Trial and controversies

Longterm toxicity of adjuvant RT after prostatectomy

EMBARK expands ENZA indication to PCa

Embark without fear

Salvage radiotherapy the new standard

Precision medicine at mCRCP

Negative data for pembrolizumab in mHSCPC & mCRPC

Osteoprotection at mHSPC

Big data and AI prediction tools

TITAN: ultra-low PSA = best prognosis

EMBARK - Quality of Life

Brave New World in mCRPC

PSMA FORE: Trial and controversies

Combination of radioligand therapy with chemotherapy…

Lu-PSMA leads forward

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor…

Immunterapi vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Part 2: New standard of care in first line urothelial…

Part1: New standard of care in first line urothelial…

Chemo-IO establishes itself in the first-line treatment…

EV + Pembro as standard of care in first-line therapy…

New SoC in firstline bladder cancer

The FGFR story in bladder cancer at ESMO23

Unique bladder delivery system of gemcitabine herolds…

DAD, DAD-IO

FGFR inhibitors: What is the best scenario for this…

When the history of ADC is written: Redefining…

Reescribiendo la historia de una enfermedad: Nuevo…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

L'histoire du FGFR dans le cancer de la vessie à…

Where does the future therapy go in renal cell…

Is de-escalating therapy ready for prime-time?

Kidney cancer highlights at ESMO23

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Intermittent therapy also possible with TKIs

New mode of action in mRCC - ready for prime time?

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+…

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with…

Perioperativ immunotherapy for all resectable stage…

My highlights from ESMO 2023

Substantial improvement in local regional NSCLC

ALINA - immediate change of practice!

Big improvements in early stage and a subset of…

Scene is set for inductive immunotherapy

Perioperative IO: OS-benefi from KEYNOTE-671

Neoadjuvant chemo-immunotherapy new standards in early…

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Perioperatieve chemo-immunotherapie voor alle patienten…

Rare oncogenic alterations: landmark results on exon 20…

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

MARIPOSA: Trial and controversies

New standard of care for metastatic EGFR exon 20…

Adagrasib + pembrolizumab in patients with KRASG12C…

Amivantamab as a new SoC for EGFR Exon 20…

NRG fusions: a new drugable target?

Amivantamab at progression? MARIPOSA-2 trial

My highlights from ESMO 2023

Changing treatment landscape in EGFR-mutated NSCLC

Brain metastases – options to improve the systemic…

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

PAPILLON - bringing together therapy for the 1st line

Big improvements in early stage and a subset of…

Amivantamab upfront? MARIPOSA trial

LIBRETO - a positive study, but was it necessary?

Practice changing results on exon 20 insertion mNSCLC

Does immunotherapy still have a place in EGFR-positive…

MARIPOSA II: Trial and controversies

By unanimous decision and still the champion –…

Substantial improvement in rare alterations

TROPION-Lung01: positive development

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Do ADCs have brain activity?

I miei punti salienti di ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR…

Amivantamab at progression? MARIPOSA-2 trial

Amivantamab upfront? MARIPOSA trial

Heeft immunotherapie nog een plek in de behandeling van…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Gros progrès dans les traitments medicaeux des stades…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

L’amivantamab, nouveau standard de traitement pour les…

A new option in relapsed SCLC

Tarlatamab in SCLC

First data on luveltamab in multiline treatment for…

PCO Therapeutics

New data on H&N Cancer

Update on gynaecological cancers

Precision oncology in CUP

Evolution of the revolution - the RUBY trial